Lipocine Inc.

Lipocine Inc. announced its financial and operational results for the third quarter ended September 30, 2026. The company reported a substantial increase in revenue to $2.3 million from $115,000 in the prior year's quarter, alongside a narrowed net loss of $0.7 million, or $0.08 per diluted share, compared to $3.2 million, or $0.59 per diluted share, in Q3 2025. The company also provided a corporate update, highlighting the initiation of the Phase 3 BLOOM study for LPCN 1154 (BRLIZIO™) for postpartum depression and regulatory approvals for TLANDO® in Canada and the UAE. Unrestricted cash reserves grew to $28.5 million.

Lipocine Inc. announced its financial results for the second quarter ended June 30, 2026, reporting a net loss of $2.6 million, or ($0.32) per diluted share. The company's cash position significantly improved to $23.3 million. A major update included the Phase 3 trial for LPCN 1154 (BRLIZIO™) for Postpartum Depression not meeting its primary endpoint, though a post hoc analysis showed positive results after excluding an outlier site. Lipocine is pursuing further development with a new trial and an FDA meeting, while also expanding its pipeline for other indications and TLANDO's international reach.

Lipocine Inc. reported a net loss of $2.62 million for Q2 2026, an increase from $2.21 million in Q2 2025, with total revenues decreasing to $0.19 million. For the first six months of 2026, the net loss widened to $6.29 million. The company significantly strengthened its financial position by raising $13.47 million through an At-The-Market (ATM) offering and received marketing authorization for TESTYRA® (TLANDO) in the UAE.

Lipocine Inc. (LPCN) filed an 8-K report detailing a virtual key opinion leader (KOL) event held on June 12, 2026. The event focused on the unmet needs in postpartum depression and presented the clinical profile of their product candidate, LPCN 1154. The presentation materials from this event have been furnished as an exhibit to the filing and are also accessible via the company's website.

Lipocine Inc. shareholders approved the Sixth Amended and Restated 2014 Stock and Incentive Plan at their annual general meeting on June 3, 2026. The amendment increases individual award limits from 25,000 to 100,000 shares and the total authorized shares for issuance under the plan by 400,000 to 1,000,000 shares. Additionally, shareholders elected four directors, ratified Tanner LLC as the independent auditor, and approved the advisory vote on executive compensation.

Lipocine Inc. announced it will host a virtual Key Opinion Leader (KOL) event on Friday, June 12, 2026, to discuss unmet needs in postpartum depression (PPD) and the clinical profile of LPCN 1154 (BRLIZIO"). The event will feature leading physicians and Lipocine management, reviewing the current PPD treatment landscape, persistent gaps in care, and Phase 3 topline results for LPCN 1154, an investigational oral brexanolone. The discussion will also cover the potential positioning of LPCN 1154 within PPD and broader depression treatment paradigms.

Lipocine Inc. presented its Phase 3 clinical data for LPCN 1154 at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting held from May 26-29, 2026. The presentation highlighted the results from the company's placebo-controlled trial evaluating LPCN 1154 (oral brexanolone) for the treatment of postpartum depression (PPD). This marks a significant update in the development of the potential PPD treatment.

Lipocine Inc. announced that its Phase 3 clinical data for LPCN 1154, an oral brexanolone for postpartum depression, has been accepted for both oral and poster presentation at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting. The oral presentation will detail results from the placebo-controlled trial, while a poster session will also feature the data. This highlights the progress of their proprietary technology platform for effective oral drug delivery.

Lipocine Inc. announced financial results for the first quarter ended March 31, 2026, and provided a corporate update. The Phase 3 trial for LPCN 1154 (oral brexanolone) for postpartum depression did not meet its primary endpoint, failing to show a statistically significant reduction in HAM-D score compared to placebo. However, the drug demonstrated a differentiated safety profile, and a post hoc analysis showed significant HAM-D reductions in patients with a history of psychiatric conditions. The company reported a net loss of $3.7 million for the quarter, an increase from $1.9 million in the prior year, while cash and equivalents rose to $24.7 million.

Lipocine Inc. reported a significant increase in net loss for the first quarter of 2026, reaching $3.67 million, up from $1.86 million in the same period last year. This was primarily driven by a substantial rise in research and development expenses. The company also raised $12.0 million in net proceeds through an At-The-Market common stock offering during the quarter, which contributed to an increase in total stockholders' equity and marketable investment securities, despite a slight decrease in cash and cash equivalents. Lipocine stated that its existing capital resources are sufficient through at least May 7, 2027, but additional capital will be needed for long-term operations.